Arvinas (NASDAQ:ARVN) Stock Rating Upgraded by Wall Street Zen

Arvinas (NASDAQ:ARVN) was upgraded by research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Sunday.

A number of other research firms have also recently weighed in on ARVN. Wells Fargo & Company decreased their price target on Arvinas from $16.00 to $15.00 and set an “overweight” rating for the company in a report on Thursday, November 6th. Barclays lifted their price objective on shares of Arvinas from $16.00 to $18.00 and gave the company an “overweight” rating in a research note on Wednesday, December 17th. Citigroup upgraded shares of Arvinas from a “neutral” rating to a “buy” rating and upped their target price for the company from $10.00 to $15.00 in a research note on Tuesday, January 6th. BTIG Research lifted their price target on shares of Arvinas from $10.00 to $14.00 and gave the stock a “buy” rating in a research note on Thursday, October 30th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Arvinas in a report on Monday, December 22nd. Ten research analysts have rated the stock with a Buy rating, eight have given a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $13.12.

Arvinas Trading Up 2.6%

ARVN stock opened at $12.30 on Friday. Arvinas has a 12-month low of $5.90 and a 12-month high of $18.93. The company has a market cap of $789.91 million, a PE ratio of -15.19 and a beta of 1.88. The stock has a 50-day moving average price of $12.36 and a two-hundred day moving average price of $10.47.

Insider Buying and Selling

In other news, insider Noah Berkowitz sold 5,685 shares of the stock in a transaction on Friday, February 13th. The stock was sold at an average price of $11.89, for a total transaction of $67,594.65. Following the completion of the sale, the insider owned 163,938 shares in the company, valued at approximately $1,949,222.82. This represents a 3.35% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Randy Teel sold 4,403 shares of the business’s stock in a transaction dated Friday, February 13th. The stock was sold at an average price of $11.89, for a total value of $52,351.67. Following the sale, the chief executive officer owned 154,482 shares in the company, valued at approximately $1,836,790.98. The trade was a 2.77% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 16,238 shares of company stock worth $193,070 over the last ninety days. 4.73% of the stock is owned by insiders.

Hedge Funds Weigh In On Arvinas

Institutional investors and hedge funds have recently bought and sold shares of the business. Tower Research Capital LLC TRC lifted its holdings in shares of Arvinas by 491.4% during the 2nd quarter. Tower Research Capital LLC TRC now owns 5,819 shares of the company’s stock valued at $43,000 after buying an additional 4,835 shares during the last quarter. Canada Pension Plan Investment Board lifted its stake in Arvinas by 109.4% in the second quarter. Canada Pension Plan Investment Board now owns 6,700 shares of the company’s stock valued at $49,000 after acquiring an additional 3,500 shares during the last quarter. State of Wyoming acquired a new stake in Arvinas in the third quarter valued at approximately $68,000. Virtus Investment Advisers LLC increased its stake in shares of Arvinas by 49.3% during the 2nd quarter. Virtus Investment Advisers LLC now owns 12,422 shares of the company’s stock worth $91,000 after purchasing an additional 4,104 shares during the last quarter. Finally, Aster Capital Management DIFC Ltd acquired a new position in shares of Arvinas during the 3rd quarter worth $92,000. Hedge funds and other institutional investors own 95.19% of the company’s stock.

About Arvinas

Arvinas, Inc (NASDAQ: ARVN) is a biopharmaceutical company focused on the development of therapies based on targeted protein degradation. Utilizing its proprietary proteolysis-targeting chimera (PROTAC®) platform, Arvinas aims to selectively eliminate disease-causing proteins rather than merely inhibit their activity. This novel approach has the potential to address a range of diseases, including oncology, neurodegeneration and inflammation, by harnessing the body’s natural protein-recycling systems.

The company’s most advanced clinical candidates address hormone-driven cancers.